A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
CUPERTINO, Calif., Sept. 07, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., Sept. 06, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial - - Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 - - $19.4 Million in Cash as of June 30, 2022 - CUPERTINO, Calif., Aug. 15, 2022 -- Reviva Pharmaceuticals...
Enrollment remains on pace for Reviva's Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022 More than 20% of the approximately 400 patients planned for Phase 3 trial...
CUPERTINO, Calif.,, June 02, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., May 17, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie Citrome, MD & Larry Ereshefsky, PharmD - Topline data for pivotal Phase 3 trial evaluating brilaroxazine for...
CUPERTINO, Calif., May 03, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, 2022 -- Reviva Pharmaceuticals Holdings, Inc....
CUPERTINO, Calif., March 24, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...